OncoMed Pharmaceuticals Inc Insider Trading for April 2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in OncoMed Pharmaceuticals Inc.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in OncoMed Pharmaceuticals Inc for April 2017.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 25 2017 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology ... | Option Exercise | A | 3.73 | 60,000 | 223,800 | 60,000 | |
| Apr 25 2017 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology ... | Grant | A | 0.00 | 20,000 | 0 | 77,225 | 57.2 K to 77.2 K (+34.95 %) |
| Apr 25 2017 | OMED | OncoMed Pharmaceut ... | Patel Sunil | See Remarks | Option Exercise | A | 3.73 | 60,000 | 223,800 | 60,000 | |
| Apr 25 2017 | OMED | OncoMed Pharmaceut ... | Patel Sunil | See Remarks | Grant | A | 0.00 | 20,000 | 0 | 44,584 | 24.6 K to 44.6 K (+81.35 %) |
| Apr 25 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Option Exercise | A | 3.77 | 135,000 | 508,950 | 135,000 | |
| Apr 25 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Grant | A | 0.00 | 45,000 | 0 | 77,586 | 32.6 K to 77.6 K (+138.10 %) |
| Apr 25 2017 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP, Research & Dev ... | Option Exercise | A | 3.73 | 67,500 | 251,775 | 67,500 | |
| Apr 25 2017 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP, Research & Dev ... | Grant | A | 0.00 | 22,500 | 0 | 45,437 | 22.9 K to 45.4 K (+98.09 %) |
| Apr 25 2017 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Option Exercise | A | 3.73 | 60,000 | 223,800 | 60,000 | |
| Apr 25 2017 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Grant | A | 0.00 | 20,000 | 0 | 63,301 | 43.3 K to 63.3 K (+46.19 %) |
| Apr 25 2017 | OMED | OncoMed Pharmaceut ... | Hager Alicia J. | SVP & General Couns ... | Option Exercise | A | 3.73 | 60,000 | 223,800 | 60,000 | |
| Apr 25 2017 | OMED | OncoMed Pharmaceut ... | Hager Alicia J. | SVP & General Couns ... | Grant | A | 0.00 | 20,000 | 0 | 41,561 | 21.6 K to 41.6 K (+92.76 %) |
| Apr 05 2017 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP, Research & Dev ... | Sell | S | 9.06 | 5,711 | 51,731 | 22,937 | 28.6 K to 22.9 K (-19.94 %) |
| Apr 05 2017 | OMED | OncoMed Pharmaceut ... | Lewicki John A. | EVP, Research & Dev ... | Sell | S | 8.87 | 43 | 381 | 28,648 | 28.7 K to 28.6 K (-0.15 %) |
| Apr 05 2017 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Sell | S | 9.06 | 5,711 | 51,731 | 43,301 | 49 K to 43.3 K (-11.65 %) |
| Apr 05 2017 | OMED | OncoMed Pharmaceut ... | Gurney Austin | See Remarks | Sell | S | 8.87 | 43 | 381 | 49,012 | 49.1 K to 49 K (-0.09 %) |
| Apr 05 2017 | OMED | OncoMed Pharmaceut ... | Patel Sunil | See Remarks | Sell | S | 9.06 | 5,711 | 51,731 | 24,584 | 30.3 K to 24.6 K (-18.85 %) |
| Apr 05 2017 | OMED | OncoMed Pharmaceut ... | Patel Sunil | See Remarks | Sell | S | 8.87 | 43 | 382 | 30,295 | 30.3 K to 30.3 K (-0.14 %) |
| Apr 05 2017 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology ... | Sell | S | 9.06 | 5,711 | 51,731 | 57,225 | 62.9 K to 57.2 K (-9.07 %) |
| Apr 05 2017 | OMED | OncoMed Pharmaceut ... | Hoey Timothy | SVP, Cancer Biology ... | Sell | S | 8.87 | 43 | 381 | 62,936 | 63 K to 62.9 K (-0.07 %) |
| Apr 05 2017 | OMED | OncoMed Pharmaceut ... | Hager Alicia J. | SVP & General Couns ... | Sell | S | 9.06 | 4,284 | 38,805 | 21,561 | 25.8 K to 21.6 K (-16.58 %) |
| Apr 05 2017 | OMED | OncoMed Pharmaceut ... | Hager Alicia J. | SVP & General Couns ... | Sell | S | 8.87 | 32 | 284 | 25,845 | 25.9 K to 25.8 K (-0.12 %) |
| Apr 05 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Sell | S | 9.06 | 6,425 | 58,199 | 32,586 | 39 K to 32.6 K (-16.47 %) |
| Apr 05 2017 | OMED | OncoMed Pharmaceut ... | HASTINGS PAUL J | Chairman & CEO | Sell | S | 8.87 | 48 | 426 | 39,011 | 39.1 K to 39 K (-0.12 %) |